Israel Englander’s AbCellera Biologics ABCL Stock Holding History

Israel Englander’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250,000	Closed	-$1.15M	–	6007
2023 Q3	$1.15M	Buy	+250,000	New	+$1.52M	﹤0.01%	4081
2023 Q2	–	Sell	-300,000	Closed	-$2.26M	–	6041
2023 Q1	$2.26M	Buy	300,000 +139,100	+86%	+$1.26M	﹤0.01%	3320
2022 Q4	$1.63M	Sell	160,900 -139,100	-46%	-$1.61M	﹤0.01%	3731
2022 Q3	$2.97M	Buy	+300,000	New	+$3.29M	﹤0.01%	3401

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Israel Englander's ABCL Position: Q2 2026 in Review

Israel Englander reduced its AbCellera Biologics (ABCL) stake by 60% in Q2 2026, selling an estimated $3.79M and leaving 518,571 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Israel Englander first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $31.5M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Israel Englander held 518,571 shares of AbCellera Biologics worth $4.07M as of Q2 2026.
Israel Englander sold 776,003 AbCellera Biologics shares in Q2 2026, an estimated $3.79M.
AbCellera Biologics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3195 holding.
Israel Englander first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
Israel Englander's AbCellera Biologics position peaked at $31.5M in Q2 2022.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.